Introduction: Hemangioma is considered the most common tumor of infancy. Rapid growth of hemangioma during its proliferative phase can lead to disfigurement and is sometimes associated with complications. Propranolol has been used recently in the treatment for infantile hemangiomas and has shown promising results. We are reporting our initial experience with the use of propranolol in treatment of hemangiomas during infancy.
Patients and methods: This study is a retrospective analysis of data of 26 patients with cutaneous infantile hemangiomas treated with oral propranolol in the hamangioma and vascular malformation clinic, Sohag Craniofacial Unit, Sohag University Hospital.
Results: Favorable response to propranolol was observed in all patients in terms of arrest of growth, reduction of size and/or fading of color of the lesion. No significant side effects were observed necessitates stopping of treatment.
Conclusion: Propranolol is an effective treatment for infantile hemangioma and should be considered as a first line therapy. Also it was safely used in infancy with no significant complications reported in our series of arrest of growth, reduction of size and/or fading of color of the lesion. No significant side effects were observed necessitates stopping of treatment.